PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24822F0241HUMAN haegarda c1 inhibitors 3000 — Csl Behring L.L.C

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Jun 3, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

248-Network Contract Office 8 (36C248)

Awarding office

Csl Behring L.L.C

Recipient

Jun 3, 2022

PoP end

$154K

Obligated

$154K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Csl Behring L.L.C — $90

Contract facts

Federal

Contract number36C24822F0241

Also listed as36C248-22-F-0241

Also listed as36F79721D0249-36C24822F0241

Agency248-Network Contract Office 8 (36C248)

Awarding office248-Network Contract Office 8 (36C248)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentCsl Behring L.L.C

CAGE07PZ8

UEIH3WKVE9VBLY3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79721D0249

Place of performanceKING OF PRUSSIA PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMay 4, 2022

PoP end (current)Jun 3, 2022

Obligated$154K

Current value$154K

Potential value$154K

HAEGARDA C1 INHIBITORS (HUMAN) 3000 UNITS is a federal award for 248-Network Contract Office 8 (36C248) held by Csl Behring L.L.C. Estimated value $154K ($154K obligated). Current period of performance ends Jun 3, 2022. Last award drew 1 bidder. Place of performance: KING OF PRUSSIA PA.

HAEGARDA C1 INHIBITORS (HUMAN) 3000 UNITS

Recompete timing

Public

● Past PoP end (1540 days ago)

Current PoP ended Jun 3, 2022 (1540 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24822F0241?

36C24822F0241 (HUMAN haegarda c1 inhibitors 3000) is a 248-Network Contract Office 8 (36C248) award with a potential value of $154K, currently held by Csl Behring L.L.C. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C248-22-F-0241?

36C248-22-F-0241 is the dashed form of PIID 36C24822F0241 (HUMAN haegarda c1 inhibitors 3000), held by Csl Behring L.L.C. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24822F0241?

248-Network Contract Office 8 (36C248) awarded 36C24822F0241 to Csl Behring L.L.C (potential $154K).

Who is the incumbent on 36C24822F0241?

Csl Behring L.L.C is the incumbent. The current period of performance ends Jun 3, 2022.

When does Csl Behring L.L.C’s 36C24822F0241 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 3, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of May 9, 2022 · refreshed monthly